Bayer and J&J aim to market Xarelto for acute coronary syndrome

10/2/2011 | Fox Business · Bloomberg

Johnson & Johnson and Bayer plan to apply by year-end for U.S. and EU authorization to promote Xarelto, or rivaroxaban, as treatment for acute coronary syndrome. The filings will include Phase III trial data showing that Xarelto combined with standard anti-clotting therapy reduces the incidence of stroke, heart attack and cardiovascular death. Xarelto was approved for certain patients undergoing surgery and recommended for preventing stroke related to atrial fibrillation.

View Full Article in:

Fox Business · Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX